**Question:** End product of purine metabolism in non-primate mammals is:

A. Inosine
B. Guanosine
C. Adenosine
D. Guanine

**Core Concept:**
Purine is a type of nitrogenous base that plays a crucial role in DNA and RNA synthesis. In mammals, purine catabolism leads to the production of different end products, depending on the species. Non-primate mammals primarily break down purines via the adenine pathway, which results in the formation of inosine monophosphate (IMP) and guanosine monophosphate (GMP).

**Why the Correct Answer is Right:**
In non-primate mammals, the primary pathway for purine catabolism is the salvage pathway, which involves the conversion of hypoxanthine to xanthine and subsequently to uric acid. This occurs in humans, making uric acid the end product of purine catabolism in primates. In contrast, non-primate mammals follow the adenine pathway, which begins with the conversion of hypoxanthine to inosine monophosphate (IMP) and then to inosine and finally to adenosine monophosphate (AMP). IMP is the correct answer as it is the end product of the adenine pathway in non-primate mammals.

**Why Each Wrong Option is Incorrect:**

A. Inosine: In non-primate mammals, the adenine pathway produces IMP, not inosine. Inosine is an intermediate in the salvage pathway, which is the primary pathway in humans.

B. Guanosine: Similar to inosine, guanosine is an intermediate in the salvage pathway in humans but not in non-primate mammals, where the adenine pathway is the primary pathway.

C. Adenosine: Adenosine is another intermediate in the salvage pathway, occurring after inosine is converted to AMP. In non-primate mammals, adenosine is not the end product of purine catabolism.

D. Guanine: Guanine is not an intermediate or end product of purine catabolism in non-primate mammals. The correct answer is IMP, which is produced in the adenine pathway.

**Clinical Pearl:**
Understanding the differences in purine catabolism pathways between non-primate mammals and humans is essential for understanding the pharmacology and toxicology of drugs that target purine pathways, such as allopurinol, a drug used to reduce uric acid production in humans. In non-primate mammals, targeting these pathways may lead to unintended consequences due to the different intermediates and end products involved.